Global Stocks Mixed as Oil Falls Ahead of US Earnings 
Elon Musk Donates $366 Million to 2026 US Midterms 
Asian Stocks Plunge as AI Chip Selloff Hits South Korea and Japan 
Nasdaq Falls as Oil Prices Surge Ahead of Bank Earnings 
Albertsons Seeks $9.3 Billion From Kroger Over Failed Merger 
Philippines Current Account Deficit Seen at $19.1 Billion in 2026 
Epic Games Delays Disney Shooter, Shifts to AI-First Development 
Bank of America Predicts Yen Rebound as USD/JPY Faces Risks 
Airbus Tests Valkyrie Combat Drone in Europe for Eurofighter Integration 
Coinbase CEO Backs SEC Accredited Investor Reform 
Trump Defends Russian Diesel Deal Amid US Sanctions Backlash 
PepsiCo Slashes Poppi Earnout Valuation as Growth Slows 
Most Americans Oppose Election Betting on Prediction Markets, Poll Finds 
IMF, World Bank Meetings Face Global Economic Risks Amid Iran War 
Hong Kong’s Second Solana ETF Launches With Lower Fees 
Gold Prices Rebound as Dollar Weakens Ahead of US Inflation Data 
S&P 500 Rally Masks Losses for Over 40% of Stocks in 2026 
Add as a preferred source on Google
Samsung Biologics revealed on Monday, Sept. 18, that it has closed a contract manufacturing organization deal (CMO) with Bristol-Myers Squibb to produce immunotherapy medications until 2030. The contract is said to be worth $242 million.
Bristol-Myers Squibb is one of the long-term customers of Samsung Biologics, so this is just another deal for a new production request. They have been working together for the CMO business since 2013. In any case, on the part of the Korean biopharmaceutical company, this contract has been added to its streak of wins for CMO projects this year alone.
Collectively, the company is close to hitting the KRW3 trillion or $2.26 billion mark for all of its deals so far in 2023. Reaching this amount is said to be a milestone for Samsung Biologics as it is happening for the first time.
As per The Korea Herald, as of September 2023, the Incheon-based biotechnology firm was able to secure contract manufacturing deals with 14 of the world’s top 20 pharmaceuticals. Novartis and Pfizer are the other major brands that signed large-scale agreements with the company.
Meanwhile, Samsung Biologics agreed to produce immunotherapies of Bristol-Myers Squibb. These will be manufactured in its fourth plant in the span of seven years.
An official of the biotech arm of the Samsung Group said, “Securing the latest deal was possible as Samsung Biologics has proved itself as a reliable contract manufacturer to its global partners, with its large production capacity, fast manufacturing speeds and consistent, high-quality output.”
“Our relationship with Bristol Myers Squibb spans over a decade, and we are proud and excited to help bring important medicines to patients around the world,” Samsung Biologics’ president and chief executive officer, John Rim, further said in a statement. “This collaboration with Bristol Myers Squibb underscores our commitment to expediting the delivery and ensuring the continuous supply of client pipelines, enabled by our commitment to manufacturing quality, innovation, and capacity.”
Photo by: Samsung Biologics Newsroom
